Ionis Pharmaceuticals, Inc.
IONS · NASDAQ
10/28/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | -0.07 | -0.20 | 0.43 |
| FCF Yield | -1.14% | 2.18% | -3.41% | -2.56% |
| EV / EBITDA | -137.51 | 49.32 | -54.02 | -83.20 |
| Quality | ||||
| ROIC | -5.81% | 5.14% | -5.71% | -4.00% |
| Gross Margin | 98.51% | 99.08% | 98.86% | 98.31% |
| Cash Conversion Ratio | 1.02 | 1.22 | 1.03 | 1.11 |
| Growth | ||||
| Revenue 3-Year CAGR | 16.28% | 14.40% | 7.59% | 6.28% |
| Free Cash Flow Growth | -198.30% | 183.91% | -15.33% | -14.18% |
| Safety | ||||
| Net Debt / EBITDA | -12.20 | 7.47 | -14.12 | -14.59 |
| Interest Coverage | -7.23 | 6.14 | -6.40 | -4.85 |
| Efficiency | ||||
| Inventory Turnover | 0.22 | 0.49 | 0.13 | 0.31 |
| Cash Conversion Cycle | -134.08 | -299.99 | -330.09 | -678.96 |